Search results
MRX Routine Normal Control
The MRX Routine Controls are suitable for the routine laboratory and are available in normal and abnormal levels.
Emicizumab Calibrator
Calibration of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.
HEMOCLOT LA-C (Confirm)
Reagent with low phospholipid concentration for confirming the presence of lupus anticoagulants (LA). The presence of LA does not or only insignificantly prolong clotting time.
Emicizumab Controls
Quality control of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.
CRYOcheck Factor VIII Deficient Plasma with VWF, frozen
Intended for use as a deficient substrate in clot-based factor VIII activity assays using the one-stage activated partial thromboplastin time (aPTT) method.
CRYOcheck Factor VIII Deficient Plasma with VWF, frozen
Intended for use as a deficient substrate in clot-based factor VIII activity assays using the one-stage activated partial thromboplastin time (aPTT) method.
MRX PT Quick (INR) Calibrator Set
MRX PT Quick (INR) Calibrator Set is intended for calibration of the MRX PT Quick reagent to determine the local International Sensitivity Index (ISI) and the Normal Clotting Time (NCT).
Factor V Deficient Plasma
Measurement of cactor V (FV / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FV deficient plasma is required
Factor V Deficient Plasma
Measurement of factor V (FV / proaccelerin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FV deficient plasma is required
Factor X Deficient Plasma
Measurement of factor X (FX or stuart factor) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human FX deficient plasma is required